{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:34:04Z","timestamp":1793363644436,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s10067-023-06567-y","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:21:34Z","timestamp":1679876494000},"page":"1847-1853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis"],"prefix":"10.1007","volume":"42","author":[{"given":"Yanhua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-3250","authenticated-orcid":false,"given":"Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"issue":"1","key":"6567_CR1","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A et al (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology 95(1):e70\u2013e78. https:\/\/doi.org\/10.1212\/WNL.0000000000009727","journal-title":"Neurology"},{"key":"6567_CR2","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F (2021) Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features Pathogenesis and Emerging Therapies. Front Immunol 12:773352. https:\/\/doi.org\/10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"issue":"3","key":"6567_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H et al (2020) Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol 72(3):488\u2013498. https:\/\/doi.org\/10.1002\/art.41105","journal-title":"Arthritis Rheumatol"},{"key":"6567_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T (2016) Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25:925\u2013933. https:\/\/doi.org\/10.1177\/0961203316651748","journal-title":"Lupus"},{"issue":"7","key":"6567_CR5","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/rheumatology\/kes012","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H (2012) Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic dermatomyositis. Rheumatology 51(7):1336\u20131338. https:\/\/doi.org\/10.1093\/rheumatology\/kes012","journal-title":"Rheumatology"},{"issue":"12","key":"6567_CR6","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M et al (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53(12):2196\u20132203. https:\/\/doi.org\/10.1093\/rheumatology\/keu258","journal-title":"Rheumatology"},{"issue":"5","key":"6567_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/bjd.16917","volume":"180","author":"SH Zhang","year":"2019","unstructured":"Zhang SH, Zhao Y, Xie QB, Jiang Y, Wu YK, Yan B (2019) Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol 180(5):1090\u20131098. https:\/\/doi.org\/10.1111\/bjd.16917","journal-title":"Br J Dermatol"},{"issue":"26","key":"6567_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J et al (2014) Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371(26):2537\u20132538. https:\/\/doi.org\/10.1056\/NEJMc1412997","journal-title":"N Engl J Med"},{"issue":"12","key":"6567_CR9","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T et al (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114\u20132119. https:\/\/doi.org\/10.1093\/rheumatology\/key188","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"6567_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in Amyopathic Dermatomyositis\u2013Associated Interstitial Lung Disease. N Engl J Med 381(3):291\u2013293. https:\/\/doi.org\/10.1056\/NEJMc1900045","journal-title":"N Engl J Med"},{"key":"6567_CR11","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, Krishnaswami S, Clark JD, Telliez JB, Dowty ME et al (2016) The mechanism of action of tofacitinib: an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318\u2013328"},{"issue":"5","key":"6567_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bjd.12517","volume":"169","author":"B Strober","year":"2013","unstructured":"Strober B, Buonanno M, Clark JD, Kawabata T, Tan H, Wolk R et al (2013) Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 169(5):992\u2013999. https:\/\/doi.org\/10.1111\/bjd.12517","journal-title":"Br J Dermatol"},{"key":"6567_CR13","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M et al (2017) 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6567_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE et al (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49\u201354. https:\/\/doi.org\/10.1093\/rheumatology","journal-title":"Rheumatology (Oxford)"},{"key":"6567_CR15","doi-asserted-by":"publisher","first-page":"6243019","DOI":"10.1155\/2020\/6243019","volume":"2020","author":"L He","year":"2020","unstructured":"He L, Shu XM, Liu X, Ge YP, Li SZ, Lu X et al (2020) Soluble IL-2 receptor in dermatomyositis: its associations with skin ulcers and disease activity. Mediators Inflamm 2020:6243019. https:\/\/doi.org\/10.1155\/2020\/6243019","journal-title":"Mediators Inflamm"},{"key":"6567_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 76:792\u2013801. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211400","journal-title":"Ann Rheum Dis"},{"key":"6567_CR17","doi-asserted-by":"publisher","first-page":"108451","DOI":"10.1016\/j.clim.2020.108451","volume":"215","author":"A Takatani","year":"2020","unstructured":"Takatani A, Koga T, Fujita Y, Fukui S, Endo Y, Shimizu T et al (2020) Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clin Immunol 215:108451. https:\/\/doi.org\/10.1016\/j.clim.2020.108451","journal-title":"Clin Immunol"},{"key":"6567_CR18","doi-asserted-by":"publisher","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","volume":"99","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kasuya T, Fujiwara M, Kita Y et al (2020) Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine 99:e21943. https:\/\/doi.org\/10.1097\/MD.0000000000021943","journal-title":"Medicine"},{"key":"6567_CR19","doi-asserted-by":"publisher","first-page":"S661","DOI":"10.1097\/RHU.0000000000001645","volume":"27","author":"Y Hosokawa","year":"2021","unstructured":"Hosokawa Y, Oiwa H (2021) A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib. J Clin Rheumatol 27:S661\u2013S662. https:\/\/doi.org\/10.1097\/RHU.0000000000001645","journal-title":"J Clin Rheumatol"},{"key":"6567_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","volume":"5","author":"SI Ohmura","year":"2021","unstructured":"Ohmura SI, Yamabe T, Naniwa T (2021) Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep 5:76\u201381. https:\/\/doi.org\/10.1080\/24725625.2020.1816674","journal-title":"Mod Rheumatol Case Rep"},{"key":"6567_CR21","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","volume":"27","author":"M Kato","year":"2019","unstructured":"Kato M, Ikeda K, Kageyama T, Kasuya T, Kumagai T, Furuya H et al (2019) Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis. J Clin Rheumatol 27:S574\u2013S577. https:\/\/doi.org\/10.1097\/RHU.0000000000000984","journal-title":"J Clin Rheumatol"},{"key":"6567_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2021.1906505","volume":"15","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T (2021) Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review. Mod Rheumatol 15:1\u20137. https:\/\/doi.org\/10.1080\/14397595.2021.1906505","journal-title":"Mod Rheumatol"},{"key":"6567_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M et al (2019) Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases. J Autoimmun 100:131\u2013136. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.003","journal-title":"J Autoimmun"},{"issue":"9","key":"6567_CR24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563\u20131570. https:\/\/doi.org\/10.1093\/rheumatology\/kes102","journal-title":"Rheumatology"},{"key":"6567_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14397595.2017.1318468","volume":"28","author":"Y Fujiki","year":"2018","unstructured":"Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S et al (2018) Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28:133\u2013140. https:\/\/doi.org\/10.1080\/14397595.2017.1318468","journal-title":"Mod Rheumatol"},{"issue":"12","key":"6567_CR26","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","volume":"32","author":"F Chen","year":"2012","unstructured":"Chen F, Wang DX, Shu XM, Nakashima R, Wang GC (2012) Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32(12):3909\u20133915. https:\/\/doi.org\/10.1007\/s00296-011-2323-y","journal-title":"Rheumatol Int"},{"issue":"1","key":"6567_CR27","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","volume":"13","author":"Y Ye","year":"2022","unstructured":"Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X et al (2022) Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun 13(1):6458. https:\/\/doi.org\/10.1038\/s41467-022-34145-4","journal-title":"Nat Commun"},{"issue":"11","key":"6567_CR28","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/art.42264","volume":"74","author":"Y Ye","year":"2022","unstructured":"Ye Y, Zhang X, Li T, Ma J, Wang R, Wu C, Wang R et al (2022) Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients With Amyopathic Dermatomyositis With Interstitial Lung Disease. Arthritis Rheumatol 74(11):1822\u20131832. https:\/\/doi.org\/10.1002\/art.42264","journal-title":"Arthritis Rheumatol"},{"key":"6567_CR29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2018.03.002","volume":"191","author":"KJ Weinhold","year":"2018","unstructured":"Weinhold KJ, Bukowski JF, Brennan TV, Noveck RJ, Staats JS, Lin L et al (2018) Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol 191:10\u201320. https:\/\/doi.org\/10.1016\/j.clim.2018.03.002","journal-title":"Clin Immunol"},{"key":"6567_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/art.40780","volume":"71","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S et al (2019) Evaluation of the Short- , Mid- , and Long- Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 71:685\u2013695. https:\/\/doi.org\/10.1002\/art.40780","journal-title":"Arthritis Rheumatol"},{"key":"6567_CR31","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1093\/rheumatology\/keaa266","volume":"59","author":"W Huang","year":"2020","unstructured":"Huang W, Ren F, Luo L, Zhou J, Huang D, Pan Z et al (2020) The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease. Rheumatology (Oxford) 59:3886\u20133891. https:\/\/doi.org\/10.1093\/rheumatology\/keaa266","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"6567_CR32","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1093\/rheumatology\/keac090","volume":"61","author":"X Gui","year":"2022","unstructured":"Gui X, Shenyun S, Ding H, Wang R, Tong J, Yu M et al (2022) Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford) 61(11):4570\u20134578. https:\/\/doi.org\/10.1093\/rheumatology\/keac090","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"6567_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2022","unstructured":"Lv C, You H, Xu L, Wang L, Yuan F, Li J et al (2022) Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk. J Rheumatol 50(2):219\u2013226. https:\/\/doi.org\/10.3899\/jrheum.220139","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T09:26:57Z","timestamp":1686734817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6567"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06567-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"29 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}